Indeed, the 50 bottom ATF4-target expressing patients (of a total of 808 AML patients) are significantly enriched for CEBPA biallelic mutations (pVal = 0.0002, binomial test). This evidence concerns the gene CEBPA and acute myeloid leukemia.